Hospital
Kaiser Foundation Hospitals
Kaiser Foundation Hospitals was paid $19.94M by Medicaid between Jan 2018 and Dec 2024, across 224 billing codes. Its largest line is 99284, emergency room visit (serious) — 28% of everything it billed.
33Billing provider infoKAISER FOUNDATION HOSPITALS
FREMONT, CA 94538
FREMONT, CA 94538
33aNPI1801960513assigned 11/17/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$19.94M
24GClaims594,055
24DCodes billed224
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#123 of 410
Median peer was paid$6.90M
This provider vs. median2.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 39,854 | $166K | |
| 2019 | 58,274 | $220K | |
| 2020 | 50,246 | $2.01M | |
| 2021 | 77,965 | $3.20M | |
| 2022 | 94,988 | $4.01M | |
| 2023 | 117,757 | $5.06M | |
| 2024incomplete | 154,971 | $5.27M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 28% | 16,806 | 14,579 | $5.53M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 5,504 | 5,303 | $2.33M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 7.4% | 6,018 | 5,828 | $1.48M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.2% | 1,786 | 1,697 | $1.44M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.7% | 2,568 | 2,526 | $947K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 3.1% | 4,742 | 4,596 | $619K |
| G0378 | Hospital observation service, per hour | 2.8% | 1,296 | 836 | $558K |
| 36415 | Collection of venous blood by venipuncture | 2.0% | 48,354 | 42,042 | $401K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.9% | 3,012 | 2,903 | $371K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.5% | 2,731 | 2,725 | $300K |
| 71046 | Radiologic examination, chest; 2 views | 1.4% | 4,206 | 4,114 | $287K |
| 71045 | Radiologic examination, chest; single view | 1.4% | 4,657 | 4,406 | $276K |
212 more codes
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.3% | 373 | $265K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.1% | 13,239 | $214K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 789 | $170K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 2,887 | $169K |
| 80061 | Lipid panel | <1% | 10,825 | $160K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,544 | $159K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 17,444 | $152K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 604 | $136K |
| 76830 | Ultrasound, transvaginal | <1% | 1,033 | $132K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,426 | $128K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,426 | $128K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 25,579 | $113K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,813 | $113K |
| 73630 | <1% | 1,268 | $109K | |
| 82565 | <1% | 32,244 | $105K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 850 | $102K |
| 82728 | <1% | 6,809 | $96K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,068 | $94K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 351 | $92K |
| 0450 | Emergency room services | <1% | 2,238 | $85K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 3,369 | $84K |
| 80051 | <1% | 15,653 | $81K | |
| 84460 | <1% | 21,813 | $79K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,532 | $78K |
| 73610 | <1% | 835 | $77K | |
| 86900 | <1% | 1,685 | $77K | |
| 85027 | <1% | 12,870 | $74K | |
| 73030 | <1% | 767 | $68K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,203 | $68K |
| 99070 | <1% | 4,066 | $65K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,860 | $60K |
| 73560 | <1% | 699 | $59K | |
| 93976 | <1% | 172 | $52K | |
| 0270 | <1% | 2,398 | $50K | |
| 86780 | <1% | 3,250 | $49K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 187 | $46K |
| 99199 | Unlisted special service, procedure or report | <1% | 894 | $46K |
| 86850 | <1% | 1,369 | $42K | |
| 73130 | <1% | 502 | $42K | |
| 73110 | <1% | 405 | $41K | |
| 86803 | <1% | 3,007 | $41K | |
| 84450 | <1% | 12,789 | $40K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,237 | $39K |
| 84132 | <1% | 9,408 | $38K | |
| 82947 | <1% | 18,520 | $34K | |
| 73564 | <1% | 280 | $33K | |
| 82247 | <1% | 11,124 | $33K | |
| 72100 | <1% | 318 | $33K | |
| 86480 | <1% | 608 | $31K | |
| 77080 | <1% | 454 | $30K | |
| 82607 | <1% | 2,193 | $29K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,472 | $28K |
| 87340 | <1% | 2,651 | $28K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,986 | $27K |
| 84153 | <1% | 1,367 | $27K | |
| 87088 | <1% | 4,476 | $26K | |
| 86901 | <1% | 1,684 | $25K | |
| 83735 | <1% | 6,713 | $25K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 266 | $25K |
| 84075 | <1% | 9,777 | $24K | |
| 83880 | <1% | 1,926 | $24K | |
| 84520 | <1% | 15,735 | $24K | |
| 83550 | <1% | 2,932 | $23K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,793 | $21K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 25 | $21K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 77 | $21K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,075 | $20K |
| 84702 | <1% | 1,943 | $20K | |
| 84484 | <1% | 4,421 | $19K | |
| 83690 | <1% | 6,846 | $19K | |
| 82043 | <1% | 3,457 | $18K | |
| 81001 | <1% | 8,126 | $18K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,238 | $18K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,621 | $17K |
| 84439 | <1% | 1,953 | $17K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 880 | $17K |
| 84295 | <1% | 3,940 | $16K | |
| 83540 | <1% | 2,962 | $16K | |
| 82310 | <1% | 3,750 | $16K | |
| 73140 | <1% | 166 | $16K | |
| 86235 | <1% | 104 | $15K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 460 | $15K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,499 | $14K |
| 82040 | <1% | 2,950 | $13K | |
| 84703 | <1% | 3,112 | $12K | |
| 86706 | <1% | 1,210 | $12K | |
| 85610 | <1% | 5,471 | $12K | |
| 73502 | <1% | 194 | $12K | |
| 86140 | <1% | 2,678 | $11K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 312 | $11K |
| 83516 | <1% | 415 | $11K | |
| 74018 | <1% | 118 | $11K | |
| 87506 | <1% | 54 | $10K | |
| 73080 | <1% | 107 | $10K | |
| 82570 | <1% | 2,131 | $10K | |
| 83655 | <1% | 711 | $10K | |
| 72141 | <1% | 37 | $10K | |
| 87040 | <1% | 1,844 | $9K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 609 | $9K |
| 71250 | <1% | 95 | $9K | |
| 84100 | <1% | 2,882 | $9K | |
| 83970 | <1% | 327 | $9K | |
| 85652 | <1% | 3,047 | $8K | |
| 80306 | <1% | 1,242 | $8K | |
| 81003 | <1% | 4,713 | $8K | |
| 83605 | <1% | 2,053 | $7K | |
| 82248 | <1% | 1,445 | $7K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,252 | $7K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 13 | $6K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,084 | $6K |
| 0637 | <1% | 27,507 | $6K | |
| 72040 | <1% | 55 | $6K | |
| 93971 | <1% | 56 | $5K | |
| 84403 | <1% | 176 | $5K | |
| 0250 | <1% | 4,515 | $5K | |
| 84156 | <1% | 1,479 | $5K | |
| 86762 | <1% | 331 | $5K | |
| 82077 | <1% | 740 | $5K | |
| 82962 | <1% | 2,834 | $5K | |
| 84550 | <1% | 971 | $5K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,623 | $4K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,560 | $4K |
| 76770 | <1% | 38 | $4K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 28 | $4K |
| J3490 | Unclassified drugs | <1% | 2,181 | $4K |
| 87631 | <1% | 147 | $4K | |
| 0710 | <1% | 899 | $4K | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 562 | $3K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 803 | $3K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 951 | $3K |
| 86704 | <1% | 213 | $3K | |
| 87517 | <1% | 90 | $3K | |
| 86225 | <1% | 179 | $3K | |
| 73590 | <1% | 27 | $3K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 139 | $2K |
| 82105 | <1% | 163 | $2K | |
| 83001 | <1% | 78 | $2K | |
| 73562 | <1% | 66 | $2K | |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 141 | $2K |
| J1815 | Injection, insulin, per 5 units | <1% | 707 | $2K |
| 86003 | <1% | 37 | $2K | |
| 82550 | <1% | 442 | $2K | |
| 85014 | <1% | 828 | $2K | |
| 84146 | <1% | 79 | $2K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 12 | $2K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,017 | $2K |
| 85379 | <1% | 609 | $2K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 12 | $2K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,035 | $1K |
| 85018 | <1% | 700 | $1K | |
| 84165 | <1% | 163 | $1K | |
| 70486 | <1% | 13 | $1K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 49 | $1K |
| 86038 | <1% | 104 | $1K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 161 | $1K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 693 | $996.43 |
| 82803 | <1% | 54 | $972.89 | |
| 80179 | <1% | 228 | $967.19 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 449 | $927.84 |
| 0301 | <1% | 590 | $917.27 | |
| 87449 | <1% | 72 | $788.80 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 309 | $684.93 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 270 | $683.83 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 107 | $653.27 |
| 0370 | <1% | 825 | $649.16 | |
| 82950 | <1% | 102 | $640.17 | |
| 87324 | <1% | 58 | $615.17 | |
| 83020 | <1% | 12 | $552.93 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 879 | $542.09 |
| 0300 | <1% | 39 | $505.63 | |
| 80069 | <1% | 81 | $379.80 | |
| 83993 | <1% | 14 | $361.00 | |
| 81025 | <1% | 37 | $334.40 | |
| 85378 | <1% | 111 | $326.69 | |
| Z7502 | <1% | 111 | $286.90 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 12 | $270.80 |
| 87209 | <1% | 12 | $236.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 12 | $204.00 |
| 87081 | <1% | 129 | $194.21 | |
| 86787 | <1% | 12 | $194.00 | |
| 87329 | <1% | 12 | $171.00 | |
| 82272 | <1% | 27 | $157.00 | |
| 86160 | <1% | 12 | $156.00 | |
| 96376 | <1% | 423 | $151.91 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 47 | $144.28 |
| 82985 | <1% | 12 | $144.00 | |
| 82746 | <1% | 15 | $135.00 | |
| 86200 | <1% | 12 | $131.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 486 | $126.50 |
| 83615 | <1% | 25 | $116.21 | |
| 87338 | <1% | 12 | $112.20 | |
| 82374 | <1% | 36 | $90.00 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 12 | $88.20 |
| 90686 | <1% | 35 | $77.80 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 18 | $68.40 |
| G0008 | Administration of influenza virus vaccine | <1% | 34 | $55.01 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 18 | $49.87 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 14 | $36.55 |
| 85007 | <1% | 14 | $10.84 | |
| 85008 | <1% | 108 | $7.56 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 49 | $1.60 |
| 0258 | 0% | 210 | $0.00 | |
| 80320 | 0% | 20 | $0.00 | |
| 3044F | 0% | 88 | $0.00 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 12 | $0.00 |
| 82435 | 0% | 15 | $0.00 | |
| 76376 | 0% | 87 | $0.00 | |
| 86765 | 0% | 24 | $0.00 | |
| 83721 | 0% | 17 | $0.00 | |
| 3046F | 0% | 12 | $0.00 | |
| 3051F | 0% | 14 | $0.00 | |
| 97161 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHANENBURG, THOMAS (SVP/AREA MANAGER)
| Provider | Location | Paid |
|---|---|---|
| Kaiser Foundation Hospitals | San Leandro, CA | $44.94M |
| Kaiser Foundation Hospitals | Hayward, CA | $1.99M |
| Kaiser Foundation Hospitals | Union City, CA | $1.40M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.